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takes longer than the traditional process of filling the mold 
with plaster. Although the time the patient is actually 
present for making the mold is a lot shorter and the patient 
doesn’t have to go through an invasive and uncomfortable 
procedure. 
Conclusions: The use of a 3D Kinect camera scanner in 
combination with a 3D printer to generate patient molds was 
implemented clinically in our institute. With this novel 
method patient comfort is increased significantly compared 
to the traditional method of using plaster cast since the 
patient doesn’t have to go through an invasive and 
uncomfortable procedure. Required patient time is less than 
a minute with an better accuracy. 
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Purpose/Objective: To develop a new treatment technique 
for prophylactic radiotherapy of the whole brain with 
avoidance of the hippocampi. This technique was 
implemented in our institute within the context of our 
participation in the 'Hippocampal Avoidance Prophylactic 
Cranial Irradiation' clinical trial (ClinicalTrials.gov 
NCT01780675). In this phase III multicentre trial patients with 
small cell lung cancer are randomised to receive Prophylactic 
Cranial Irradiation (PCI) with or without Hippocampal 
Avoidance (HA). 
Materials and Methods: The Hippocampal Avoidance Zone is 
defined as both hippocampi (left and right) extended with a 
margin of 5 mm. The Planning Target Volume (PTV) is defined 
as the brain extended with a margin of 4 mm minus the 
Hippocampal Avoidance Zone. The goal was to deliver 25 Gy 
to at least 95% of the PTV in 10 fractions, while sparing the 
hippocampi (mean dose < 8.5 Gy; max dose < 10 Gy) and eye 
lenses (max dose < 10 Gy). 
A coplanar VMAT technique with two dual arcs was planned 
using Pinnacle3 v9.8 (Philips). Overnight optimization was 
performed using a homemade script to repeat SmartArc 
optimizations at a 3mm dose grid until no further decrease in 
cost function was obtained. For this study, HA-PCI treatment 
plans with a controlpoint-spacing (CPS) of 4° as well as 2° 
were created for 7 patients. Subsequently, the plans were 
delivered on an Elekta linac with an Agility MLC (5mm 
leaves). Pre-treatment delivery-QA was performed by 
measuring the dose distribution using a cylindrical diode-
array phantom (Delta4, ScandiDos). The measured dose 
distributions were compared to the TPS calculations using a 
4%/2mm gamma criterion, aiming for a pass rate >95%. 
Planning parameters as well as QA measurement results were 
compared for the 4° and 2° plans. 
Results: The dose distribution of a typical HA-PCI treatment 
plan is shown in Figure 1. Planning parameters and QA 
measurement results of the 4o and 2o CPS plans for 7 patients 
are shown in Table 1. All plans achieved a homogeneous 
coverage of the PTV, while the objectives and constraints as 
defined in the study protocol were accomplished. QA 
measurements for the treatment plans with a CPS of 4° 
showed better agreement with the TPS calculations than the 
2° CPS plans, with an average pass rate of 95.4% at a 
4%/2mm gamma criterion (range 91.5 – 99.1%). 
 
 
Figure 1: Dose distribution of a clinical Hippocampal 
Avoidance Prophylactic Cranial Irradiation treatment plan, 
showing suitable coverage of the PTV (red colorwash) by the 
95% isodose level (23.75 Gy, thick yellow line), without high 
dose regions exceeding 110% (27.50 Gy), and adequate 
sparing of both hippocampi (green colorwash) at a dose level 
below 10 Gy (light blue isodose-line). 
Table 1. Planning parameters and QA measurement results of 
the 4o and 2o controlpoint spacing (CPS) plans of 7 patients. 
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Conclusions: A linac-based coplanar VMAT technique for HA-
PCI was developed, providing high quality treatment plans 
meeting all the study objectives.  
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Purpose/Objective: The complexity of IMRT techniques 
makes patient-specific verification a prerequisite, and the 
use of Portal Dosimetry has practical advantages. 
The purpose is to validate the Portal Dosimetry system 
against the standard QA system (diode array 2D), in order to 
use it for routine QA. 
Materials and Methods: 
-2D diode matrix Sun Nuclear MapCHECK2™ (standard check 
device)  
-Linac Varian Clinac™ 2100C/D with portal vision type AS500™ 
(PV) 
-Philips Pinnacle™ Treatment Planning system version 9.8 
(TPS) 
-Sun Nuclear™ software: SNC Patient™, EPIDose™, and 3DVH™. 
The EPIDose™ was commissioned for dosimetric measures 
(two models were made for gray level to dose conversion, 
one for 100cm and other for 130cm SDD). The 130cm model 
has greater resolution and allows higher dose rate (DR), but 
with smaller field size. From EPIDose™ or MapCHECK2™ data, 
SNC Patient™ generates a 'Perturbated dose matrix', the 3D 
dose distribution from the measures. 3DVH™ compares it with 
the calculated dose matrix from the TPS. It’s a volumetric QA 
system. 
38 QA measures were made in both devices for 22 different 
treatment plans (12 prostate and 26 Head and Neck (H&N) 
cases). All passed the standard MapCHECK2™ test. 
The validation process analyzes: 
- Dose coincidence with Portal Dosimetry and 3DVH™ for the 
whole body (see figure below), targets and organs at risk, 
using the global gamma criterion (3%-3mm) with matching 
rate of 95%. 
- Difference of these values with those of MapCHECK2™ array. 
- Portal Dosimetry passing rates (% of plans ok)  
- Concordance of the two EPIDose™ models used (distance 
100 cm and 130 cm). 
- Reproducibility of the measures. 
 
 
 
 
Results: 
 
- Average % passing points (1) are all over 95% with Portal 
Dosimetry. 
- Passing rate differences in 3DVHs (2) shows greater 
coincidence with TPS for MapCHECK2™ than for EPIDose™ 
(negative values).  
- In 71 % of cases the plan was ok in both devices (3) (100% 
using matching rate of 90%). The results are ≈30% better for 
prostate. 
- Concordance: 14 cases. Mean difference: 0.27%. SD: 2.65% 
- Reproducibility: 6 Cases: difference range: 0.2% - 4.3% 
 
Conclusions: The portal vision system together with EPIDose™ 
and 3DVH™ can be used for IMRT QA in prostate cases. 
Further modeling effort should be done with H&N. 
The measure time is greater with EPIDose™ due to the lower 
dose rate. But it could be faster if the number of treatments 
is low, because of the set-up time. 
The lower EPIDose™ passing rates are due to its bigger spatial 
resolution (lower pixel size): It is more restrictive than 
MapCHECK2™ and can detect smaller hot/cold spots. 
It has the inconvenient of not being able to take into account 
the MU/dose equivalence. However, this way it is a 
redundant check of the MU/Dose equivalence (measures 
closer to real treatment conditions). 
The 130cm distance model shows better results. Greater 
differences have been detected on the edge of fields because 
of the greater ratio border/area for this SSD. 
   
